Morphologic evidence of anti-tumor specificity of T cells activated by denritic cells derived from peripheral blood mononuclear cells of thyroid cancer patients

Korean Journal of Physiology and Pharmacology

Volumn 16, Issue 4, 2012, Pages 243-247

  Lee, Dae Heui ^a  

^a Kosin University College of Medicine   (South Korea)

Author keywords

Anti tumor specificity; Cytotoxic T lymphocytes (CTLs); Dendritic cells; Immunotherapy; Thyroid cancer

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER TISSUE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SPECIFICITY; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPHENOTYPING; PERIPHERAL BLOOD MONONUCLEAR CELL; SCANNING ELECTRON MICROSCOPE; T LYMPHOCYTE ACTIVATION; THYROID CANCER;

EID: 84865815630     PISSN: 12264512     EISSN: None     Source Type: Journal    
DOI: 10.4196/kjpp.2012.16.4.243     Document Type: Article

References (19)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol. 1991;9:271-296.
2. Lee DH, Park JS, Eo WK, Kim WM, Kang K. Differentiation induction of dendritic cell phenotypes from human leukemic cell lines. Korean J Physiol Pharmacol. 2001;5:79-86.
3. McKenna HJ, de Vries P, Brasel K, Lyman SD, Williams DE. Effect of flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells. Blood. 1995;86:3413-3420.
4. Young JC, Varma A, Digiusto D, Backer MP. Retention of quiescent hematopoietic cells with high proliferative potential during ex vivo stem cell culture. Blood. 1996;87:545-556.
5. Piacibello W, Sanavio F, Garetto L, Severino A, Bergandi D, Ferrario J, Fagioli F, Berger M, Aglietta M. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood. 1997;89:2644-2653.
6. Lyman SD, James L, Johnson L, Brasel K, de Vries P, Escobar SS, Downey H, Splett RR, Beckmann MP, McKenna HJ. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood. 1994;83:2795-2801.
7. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature. 1998;395:82-86.
8. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML. The immunological synapse: a molecular machine controlling T cell activation. Science. 1999;285:221-227.
9. Lanzavecchia A, Lezzi G, Viola A. From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell. 1999;96:1-4.
10. Lanzavecchia A, Sallusto F. Antigen decoding by T lymphocytes: from synapses to fate determination. Nat Immunol. 2001;2:487-492.
11. Pardoll DM. Cancer vaccines. Nat Med. 1998;4 5 Suppl:525-531.
12. Ockert D, Schmitz M, Hampl M, Rieber EP. Advances in cancer immunotherapy. Today. 1999;20:63-65.
13. Nestle FO, Burg G, Dummer R. New perspectives on immunobiology and immunotherapy of melanoma. Immunol Today. 1999;20:5-7.
14. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol. 1996;24:859-862.
15. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med. 1997;186:1183-1187.
16. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg. 1997;226:1-5.
17. Colaco CA. DC-based cancer immunotherapy: the sequel. Immunol Today. 1999;20:197-198.
18. Bottomly K. T cells and dendritic cells get intimate. Science. 1999;283:1124-1125.
19. Lee DH. Dendritic Cells-based vaccine and immune monitoring for hepatocellular carcinoma. Korean J Physiol Pharmacol. 2010;14:11-14.